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Dwarfism and low insulin-like growth factor-1 due to dopamine
depletion in Pts-/- mice rescued by feeding neurotransmitter
precursors and H4-biopterin
Abstract
The tetrahydrobiopterin (BH4) cofactor is essential for the biosynthesis of catecholamines and serotonin
and for nitric-oxide synthase (NOS). Alterations in BH4 metabolism are observed in various
neurological and psychiatric diseases, and mutations in one of the human metabolic genes causes
hyperphenylalaninemia and/or monoamine neurotransmitter deficiency. We report on a knockout mouse
for the Pts gene, which codes for a BH4-biosynthetic enzyme. Homozygous Pts-/- mice developed with
normal morphology but died after birth. Upon daily oral administration of BH4 and neurotransmitter
precursors the Pts-/- mice eventually survived. However, at sexual maturity (6 weeks) the mice had only
one-third of the normal body weight and were sexually immature. Biochemical analysis revealed no
hyperphenylalaninemia, normal brain NOS activity, and almost normal serotonin levels, but brain
dopamine was 3% of normal. Low dopamine leads to impaired food consumption as reflected by the
severe growth deficiency and a 7-fold reduced serum insulin-like growth factor-1 (IGF-1). This is the
first link shown between 6-pyruvoyltetrahydropterin synthase- or BH4-biosynthetic activity and IGF-1.
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Abstract
The tetrahydrobiopterin (BH4) cofactor is essential for the biosynthesis of
catecholamines and serotonin, and for NOS. Alterations in BH4 metabolism are
observed in various neurologic and psychiatric diseases, and mutations in one of the
human metabolic genes causes hyperphenylalaninemia and/or monoamine
neurotransmitter deficiency. We report on a knockout mouse for the Pts gene, which
codes for a BH4-biosynthetic enzyme. Homozygous Pts-/- mice developed with
normal morphology but died after birth. Upon daily oral administration of BH4 and
neurotransmitter precursors the Pts-/- mice eventually survived. However, at sexual
maturity (6 weeks) the mice had only one third of the normal body weight and were
sexually immature. Biochemical analysis revealed no hyperphenylalaninemia, normal
brain NOS activity, and almost normal serotonin levels, but brain dopamine was 3% of
normal. Low dopamine leads to impaired food consumption as reflected by the severe
growth deficiency and a 7-fold reduced serum insulin-like growth factor-1 (IGF-1).
This is the first link shown between PTPS- or BH4-biosynthetic activity and IGF-1.
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INTRODUCTION
Tetrahydrobiopterin (BH4) plays a central essential role in metabolism, involving
monoamine neurotransmitter biosynthesis, hepatic phenylalanine degradation, and nitric
oxide (NO) production. The absolute requirement of BH4 for such enzymatic functions
is reflected by severe disturbances or even lethality in the case of cofactor limitation due
to mutations in BH4-metabolic genes. Patients with cofactor deficiency may exhibit
severe dopamine and serotonin neurotransmitter deficiency, hyperphenylalaninemia,
and reduced NO production (1,2).
The BH4 cofactor is synthesized from guanosine triphosphate (GTP) by a set of
reactions involving three enzymes. GTP cyclohydrolase I (GTPCH), the first enzyme in
BH4 biosynthesis, catalyzes the formation of dihydroneopterin triphosphate from GTP
(3). GTPCH activity is regulated by its substrate GTP, BH4, and phenylalanine. A
physiological mechanism for posttranslational control of GTPCH activity involves
feedback inhibition by BH4. Notably, feedback inhibition results from BH4-induced
complex formation of GTPCH with a regulatory protein known as GTPCH feedback
regulatory protein (GFRP) (4-6). In the second step, the 6-pyruvoyl-tetrahydropterin
synthase (PTPS) catalyzes the conversion of dihydroneopterin triphosphate to 6-
pyruvoyl-tetrahydropterin. PTPS needs to be phosphorylated to be fully active (7,8).
Sepiapterin reductase (SR) is required for the final step reductions of the diketo
intermediate, 6-pyruvoyl-tetrahydropterin to BH4. 
BH4 is required as cofactor for phenylalanine hydroxylase (PAH), tyrosine hydroxylase,
and tryptophan hydroxylase. The latter two are key enzymes in the biosynthesis of the
neurotransmitters dopamine and serotonin (9). The complete hydroxylating system of
aromatic amino acids consists of the two additional BH4-regenerating enzymes: pterin
4-α-carbinolamine dehydratase (PCD) and dihydropteridine reductase (DHPR) (10).
BH4 is also required for the nitric oxide synthase enzymes (11). 
A deficiency of phenylalanine catabolism, leading to hyperphenylalaninemia (HPA),
comprises a heterogeneous group of disorders caused by a partial or complete
deficiency of the hepatic apoenzyme PAH, or by one of the enzymes involved in
cofactor biosynthesis (GTPCH or PTPS) (12,13), or regeneration (DHPR and PCD)
(14-16). Whereas severe HPA, leading to classical phenylketonuria, can only be treated
with phenylalanine-low diet, patients with BH4–responsive PAH deficiency can be
treated with BH4 alone (17). Two disorders of BH4 metabolism may present without
HPA. These are dopa-responsive dystonia (DRD or Segawa disease) (18) and
sepiapterin reductase deficiency (19,20). While DRD is caused by a mutation in the
GTPCH gene and is inherited in an autosomal dominant manner, SR deficiency is an
autosomal recessive trait. Both diseases manifest severe biogenic amine deficiencies. 
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To diagnose BH4 deficiencies and follow-up of the resulting pathologies, only limited
possibilities are available, including measurements of metabolites in body fluids, and
follow-up of the disease development almost exclusively under treated conditions.
Diagnosis starts in most cases with screening of HPA with the Guthrie card and
determination of plasma phenylalanine levels as an indirect measurement of hepatic
phenylalanine hydroxylase (PAH) activity. Analysis of phenylalanine and tyrosine in
serum or plasma before and after a BH4 challenge are often applied as an additional
diagnostic tool for differentiation between classical phenylketonuria and biopterin
variants. Furthermore, urinary pterin analysis and enzymatic measurements in
erythrocytes or skin fibroblasts are carried out to gather information on biopterin-
metabolizing enzymes. These data are then combined with a neurotransmitter status. For
neurotransmitters, the dopamine and serotonin neurotransmitter degradation products
homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA), respectively, are
measured in cerebrospinal fluid (CSF), thus following the activities of tyrosine and
tryptophane hydroxylases. Furthermore, NO metabolites at least for brain NO-synthase
(NOS) isoenzyme activity are determined in CSF.
Symptoms of BH4 deficiency include a vast range of abnormalities of the central
nervous system, including microcephaly, seizures, hypertonia, hypersalivation,
temperature instability, feeding difficulties, and mental retardation. The goals of
treatment are to control HPA by dietary restriction of phenylalanine (in PAH
deficiency) or BH4 administration (in GTPCH and PTPS deficiency), and to restore
neurotransmitter homeostasis by oral administration of the dopamine and serotonin
precursors L-Dopa and 5-hydroxytryptophan, respectively, in BH4 deficiencies. Late
detection and introduction of treatment leads to irreversible brain damage. For patients
with BH4 deficiency, HPA is controllable with oral doses of 2-10 mg synthetic
BH4/kg/day. However, such relatively low doses of BH4 do not allow the cofactor to
penetrate the blood-brain barrier efficiently (21,22). To some extent, this problem can
be overcome by administering higher doses of BH4, up to 20 mg/kg/day, together with
corresponding neurotransmitter precursors (23). The combined therapy is mandatory to
avoid neurological damage; however, this treatment is not sufficient in every case (24). 
In order to analyze in more detail the consequences of BH4 deficiency and its treatment,
and to study pathologies in the organism, the use of animal models is required. Here we
report on the generation of an animal model for PTPS deficiency by knocking out the
 Pts gene in the mouse. This led to perinatal lethality of otherwise normal born animals.
Treatment studies with daily oral administration of different concentrations of BH4, L-
Dopa, and 5-hydroxytryptophan for BH4 led to the observation, that mice can be
rescued but exhibit severe growth deficiency leading to dwarfism due to low serum
insulin-like growth factor-1 (IGF-1).  
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EXPERIMENTAL PROCEDURES
Pts gene targeting
 A genomic clone containing the Pts gene encoding the mouse PTPS was isolated from
a 129/Sv-λ phage library and characterized previously (25). To construct a targeting
vector, a KpnI-NcoI fragment, generated by PCR and spanning exon 1 and the first 9
codons from exon 2 were used for the short arm of homology (Fig. 1A). Exon 2 of this
fragment was ligated in-frame with an NcoI-BamHI fragment containing the
prokaryotic lacZ gene, followed by a phosphoglycerate kinase promoter (Pgk)-neo 
cassette. A Pgk-tk cassette was added 5’ to this short arm of homology. The long arm
of homology was a 5.4 kb HindIII fragment containing exons 5 and 6 of the Pts gene.
The final targeting vector, plasmid pMSY23, was linearized, electroporated into 129/Sv
embryonic stem (ES) cells and selected for G418 and FIAU resistance as described (26).
For PCR screening of ES clones, a nested PCR with two rounds of 40 cycles under
standard amplification conditions with an annealing temperature of 55°C was applied.
For the first PCR, the 5’ primer MSY69 annealed outside (upstream) of the short arm of
homology, and the 3’ primer PLACZ6 matched to the lacZ gene. For the second round
of amplification, the 5’ primer MSY70 was upstream of exon 1, and the 3’ primer
PLACZ7 again in the LacZ gene (MSY69: 5’-
TATATGCCATCTCTGACTGACAACA-3’; MSY70: 5’-
CTGTCTCTGGTTTGAGGAAGTCTCT-3’; PLACZ6: 5’-
CAGTTTGAGGGGACGACGACAGTAT-3’; PLACZ7: 5’-
TGCTGTTTCTGGTCTTCACCCACCG-3’). Upon additional confirmation of correct
double cross-over by Southern blot analyses with an outside probe A (see Fig. 1C), or
an internal probe B (not shown) positive Pts+/- ES cell sub-clones were used for
injection into C57BL/6 blastocysts, generation of chimeras (derivatives of ES cell-
subclone 7-E3), and breeding of homozygous Pts-/- 129/Sv-C57BL/6 hybrid mice.
Screening of mouse tissue material (tail biopsies) was performed by a complex PCR
with 40 cycles and 3 primers, and an annealing temperature of 53°C. Primers: MSY107
(a): 5’-TGACTATGGGCAGAGTTGTT-3’; MSY108 (b): 5’-
GATTGTTGCATTTCCCAAAC-3’; PLACZ8 (c): 5’-GGCTCAGTTCGAGGTGCT-
3’ (see also Figure 1B). β-Galactosidase activity was determined with extracts from ES
cells according to a published protocol (27).  
Replacement therapy
For an overview of concentrations of drugs used for treatments, see Table 1. For the
‘low‘ treatment, tablets from Schircks Laboratories (Jona, Switzerland) containing 50
mg BH4, 50 mg ascorbic acid, and 25 mg N-acetyl-L-cysteine were dissolved in 10 ml
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H2O. For L-Dopa, tablets containing 100 mg Levodopa and 25 mg Carbidopa (Sinemet
MSD, Glattbrugg, Switzerland), and for 5-hydroxytryptophan, tablets containing 100
mg Oxitriptanum (Sigma-tau) were each dissolved in 20 ml of H2O. For the ‘medium’ 
and ‘high’ treatment, the following stock solutions were prepared: 65 mg of BH4 x 
2HCl together with 50 mg of ascorbic acid (Schircks Laboratories, Jona, Switzerland)
dissolved in 1 ml H2O, 10 mg L-Dopa (Sigma) dissolved in 1 ml H2O, 6 mg 5-
hydroxytryptophan (Sigma) dissolved in 1 ml H2O, 2.5 mg Carbidopa (Sigma)
dissolved in 1 ml H2O, and 25 mg N-acetyl-L-cysteine (Sigma) dissolved in 1 ml
H2O. To determine the actual concentrations of BH4, L-Dopa, and 5-hydroxytryptophan,
the dissolved compounds were analyzed by standard HPLC (see below). Aliquots were
kept frozen, thawed before use, and mixed for the amount required according to Table
1. The freshly prepared solutions were orally administered using yellow tips and a
Gilson micropipette. For the ‘medium’ and ‘high’ treatment protocols, the daily aliquots
were divided into 2 daily doses. 
Preparation of mouse tissues
After scarifying the animals, brains and livers were withdrawn immediately for
preparing tissue homogenates. Homogenizing buffer containing 50 mM Tris-HCl, pH
7.5, 0.1 M KCl, 1 mM EDTA, 1 mM dithiothreitol, 0.2 mM phenylmethylsulfonyl
fluoride, 1 µM leupeptin, and 1µM pepstatin was added to whole brain (4 µl/mg tissue),
or liver (5 µl/mg tissue). Tissues were blended at 4°C with an electric homogenizer
(Kinematic GmbH, Littau-Luzern, Switzerland), and centrifuged at 15000 g for 20
minutes at 4°C. Supernatants were kept frozen at 80°C. 
Neopterin and biopterin measurements
A volume of 50 µl of liver or 50 µl of brain tissue homogenates were adjusted to 100
µl, and oxidized with 10 µl of oxidizing solution (5 g/l iodine and 10 g/l potassium
iodide in 1 M HCl). After oxidation in the dark for 60 minutes, the reaction was stopped
by adding 10 µl of freshly prepared ascorbic acid (20 g/l). A total of 14 µl of 1 M NaOH
was added to adjust the mixture to pH 8.5, followed by incubating with 20 µl of an
alkaline phosphatase solution at 37°C for 1 hour  (300 U/ml calf intestine alkaline
phosphatase from Roche in 0.1 M Tris-HCl, pH 8.0, 1 mM MgCl2, 0.1 mM ZnCl2).
The mixture was adjusted to pH 2 by adding 5 µl of 2 M HCl, and deproteinized through
an Ultrafree-MC filter (Millipore). Neopterin and biopterin are measured from the
filtrate by HPLC (28). The concentrations are expressed as pmol per mg of protein.
Enzymatic assays
A volume of 100 µl tissue homogenates were desalted on a spin column (MicroSpinTM
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G-25 columns, Amersham Pharmacia Biotech), and 100 µg of protein from the liver
filtrate or 200 µg of protein from the brain filtrate were used for GTPCH and PTPS
assays, respectively. 
GTPCH assay: a final volume of filtrate was adjusted to 50 µl and was added to 148 µl
homogenizing buffer and 2 µl of 100 mM GTP (Roche). This mixture was divided into
two 100-µl portions. One portion was immediately oxidized as blank with cell extract
and the second portion was incubated for 60 minutes at 37°C. The reaction was stopped
by cooling the sample on ice and adding 10 µl of oxidizing solution (5 g/l iodine and 10
g/l potassium iodide in 1 M HCl). After oxidation in the dark for 60 minutes, the
reaction was stopped by adding 10 µl of 20 g/L ascorbic acid (freshly prepared). The
mixture war adjusted to pH 8.5 by adding 14 µl of 1 M NaOH, and the sample was
incubated with 20 µl of alkaline phosphatase solution at 37°C for 1 hour (300 U/ml calf
intestine alkaline phosphatase, Roche; see above). The mixture was adjusted to pH 2 by
adding 5 µl of 2 M HCl, and deproteinized through an Ultrafree-MC filter (Millipore).
Neopterin was measured from the filtrate by HPLC. One unit of GTPCH produces 1
µmol of neopterin per minute at 37°C. 
PTPS assay: a final volume of filtrate was adjusted to 50 µl and was added to 60 µl of
reaction mixture (100 mM Tris-HCl, pH 7.4, 10 mM MgCl2, 1 mM NADPH, 1 mM
NADH, 3 mU of SR, 140 mU of DHPR from Roche, and 60 µmol/L dihydroneopterin
triphosphate) in a final volume of 110 µl. This mixture was divided into two portions,
one 50-µl aliquot was incubated for 2 hours at 37°C and another 50 µl was used as a
blank. A blank without cell extract was incubated at the same time; it contained 50 µl of
reaction buffer and 60 µl of reaction mixture. The reaction was stopped by adding 15 µl
of 300 g/l trichloroacetic acid (TCA) for protein precipitation, and cooling on ice for at
least 10 minutes, followed by oxidation with 5 mg MnO (manganese oxide) for 15
minutes in the dark. For the blanks, the same procedure was used. After 2 minutes of
centrifugation at 15’000 g, the supernatant was deproteinized through an Ultrafree-MC
filter (Millipore) and analyzed by HPLC. One unit of PTPS produces 1 µmol of
biopterin per minute at 37°C.
NO assay: the NO, which is the product of NOS, is extremely reactive and undergoes a
series of reaction. Nitrite (NO2-) and Nitrate (NO3-) are the final products. The sum of
these two products (nitrite+nitrate) was measured using a commercial Colorimetric
Assay Kit (Cayman Chemical, Ann Arbor, MI, USA). During this assay, Nitrate was
converted to nitrite utilizing nitrate reductase and measured with the Griess reagent.
Absorbance was read at 570/620 nm in a MicroELISA autoreader MR 530 (Dynatech,
Chantilly, VA, USA)
Phenylalanine hydroxylase (PAH) assay: the assay was adapted from Ledley et al. (29).
Liver homogenate containing 50-100 µg of total protein was used for PAH assay. For
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the blank, the appropriate amount of liver homogenate was adjusted to a final volume of
104 µl with water, and incubated for 5 min in a 96°C heating block. For the sample, the
appropriate amount of liver homogenate was adjusted to a final volume of 77.5 µl with
water. A volume of 22 µl of master mixture was added to each sample. The master
mixture contained 0.6 mM phenylalanine, 3.6 U catalase (Sigma), 0.15 M KCl in a 0.2
M potassium phosphate buffer, pH 6.8. After pre-incubation at room temperature, the
reaction was started by adding 2 µl of 4.5 mM 6-methyl-tetrahydropterin (6M-PH4, 
Shircks Laboratories, Jona, Switzerland) to the samples, and incubated for 60 minutes at
25°C. The reaction was stopped by incubation for 5 minutes in a 96°C heating block,
and centrifuged for 5 min at 13000 rpm. The supernatant was filtrated in an Ultrafree-
MC filter device and centrifuged again at 5000 g for 15 min. Phenylalanine and tyrosine
were quantified with a standard amino acid analyzer (Biochrom 20 Plus, Amersham
Pharmacia Biotech).
Phenylalanine concentration in the blood
The blood from the mice was collected on filter paper cards (Guthrie card).
Phenylalalnine (and tyrosine) concentrations were measured using electrospray
ionization tandem mass spectrometry (ESI-MS/MS).
Protein measurement
Protein concentrations in homogenized tissues, wes determined by the
spectrophotometric method described by Bradford, using γ-globulin as a calibrator (30).
The activities of the various enzymes are expressed as units per mg protein.
Immunoassays
Blood was collected from 35 and 44-day-old mice at the time animals were
sacrificed. 
Insulin-like growth factor-1 (IGF-1): serum IGF-1 was separated from clotted blood
by centrifugation. It was measured after extraction with acid-ethanol (40 µl serum
and 160 µl acid-ethanol). The mixture was incubated for 30 min at room temperature,
centrifuged and 100 µl supernatant was diluted 1:6 before analysis. Serum IGF-1 was
determined by radioimmunoassay (RIA) using a rat IGF-1 RIA Kit (DSL-2900,
Bühlmann laboratories AG, Switzerland). 
Growth hormone (GH): serum GH was measured by RIA using a specific rabbit anti-
rat antiserum and rat GH as standard. The rat GH RIA Kit (AH R012) was obtained
from Bühlmann laboratories AG (Switzerland). 
Blood thyroxin (T4): T4 was measured by fluoroimmunoassay using the mouse anti-
thyroxine IgG as first antibody and the anti–mouse IgG as second antibody. The blood
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was dried on filter paper cards (Guthrie card). The total amount of T4 was determined
in the test. The AutoDELFIATM Neonatal Thyroxine (T4) kit  was obtained from
Perkin Elmer, Life Sciences, Wallac-ADL AG (Switzerland). 
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RESULTS
Targeted deletion of the mouse Pts leads to perinatal death
A targeting construct was generated based on the previously isolated and characterized
mouse gene structure Pts, encoding the 6-pyruvoyl-tetrahydropterin synthase (25). As
shown in Fig. 1A, the pMSY32-targeting vector contained an in-frame lacZ gene
fusion at exon 2 of the Pts gene, expressing a putative PTPS-β-galactosidase fusion
with 35 N-terminal amino acids from PTPS. Downstream of the LacZ gene, a Pgk-neo 
cassette was inserted in the opposite direction. Upon correct homologous recombination
in ES cells, a putative mutant allele is generated with the lacZ and Pgk-neo inserted,
and a deletion of exons 3 and 4, plus most of exon 2. The targeting frequency for correct
double cross-over in the 129/Sv ES cells, as verified by PCR, was approx. 5% (not
shown). These ES cells had a β-galactosidase activity of 0.05-0.12 OD/mg (wild-type
activity <0.001 OD/mg) and a PTPS activity indistinguishable from wild-type (5.4-6.5
 µU/mg). 
Upon PCR and Southern blot analyses (Fig. 1B and C), a few Pts+/- ES cell clones
were used for blastocyste injection and subsequent generation of PTPS-null mice.
Homozygous mice developed with normal morphology in utero, and were born at the
expected Mendelian ratio (25% wild-type, 48% heterozygotes, 27% Pts-null mice; n =
159). However, most of the Pts-/- mice died within the first hours after birth; at
maximum we found 4 mice out of 26 surviving for 7 days. A more detailed analysis of
brain development and fine-structure of Pts-/- mice will be published elsewhere (in
preparation). Southern blot analyses with genomic mouse tail DNA and a 5’-external
probe (Fig. 1C), or an internal neo-probe (‘Probe B’ in Fig. 1A; results not shown)
revealed correct homologous recombination at the single mouse Pts gene locus. As
compiled in Table 2, newborn knockout mice at day 1 had no PTPS (<0.05 µU/mg) and
normal GTPCH activity (0.1-0.3 µU/mg). Heterozygous animals showed intermediate
PTPS activity (1.5 µU/mg) compared to normal activity in wild-type mice (8.0 µU/mg).
Liver neopterin was almost 200-fold higher than normal (59.0 pmol/mg in Pts-/-), and
biopterin was only 4% of wild-type (0.9 pmol/mg). Furthermore, the Pts-/- animals
had hyperphenylalaninemia with blood values of 1352 µmol/l phenylalanine (normal
control levels were between 34-85 µmol/l), and no detectable or very low brain
dopamine and serotonin levels. Expression of β-galactosidase was observed in
heterozygous and homozygous Pts mutants (not shown). A more detailed study on
developmental expression of the PTPS-LacZ fusion will be published elsewhere.
Treatment of Pts-/- mice resulted in rescue from lethality but severe dwarfism
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In a next step, we thought to rescue the knockout mice by applying a replacement
therapy protocol based on the recommended standard concentrations for treatment of
human PTPS patients (1). This included daily oral administration of BH4 to control
blood phenylalanine, and the neurotransmitter precursors L-Dopa and 5-
hydroxyptryptophan. Unexpectedly we learned that with this standard treatment
protocol, Pts-/- mice survived not longer than for about 3 weeks. We thus extended our
treatment studies with three types of application levels (Table 1; see also Experimental
Procedures): standard or ‘low’ treatment, a ‘medium’ treatment with 2-5-times higher
concentrations of BH4 and neurotransmitter precursors, and a ‘high’ treatment with
roughly 3-10-times higher concentrations. Each treatment group contained 7-14
control animals, i.e. wild-type or heterozygotes, and 3-6 Pts-/- mice. The body weight
of every single animal was monitored daily, and is depicted for each treatment group in
Fig. 2. 
As mentioned before, the Pts-/- animals with the ‘low’ treatment did not survive for
more than 3 weeks. A similar situation was encountered with the ‘medium’ treatment,
where survival of the Pts-/- animals was prolonged but they eventually died between
day 31 and 40 after birth (at a certain point knockout animals had to be sacrificed due to
progressively poor conditions, and in agreement with the Rules and Guidelines for the
Care and Use of Laboratory Animals of the State of Zurich). In contrast, all Pts-/- 
animals with the ‘high’ treatment survived and were in relatively good health
conditions. The experiment was stopped after 6 weeks of treatment, where all animals
were sacrificed for biochemical analysis (see below). As shown in Fig. 2A-C, newborn
mice regardless of the treatment mode gained weight without significant differences
between genotypes for about 2 weeks, and underwent pronounced growth retardation
during week 3 (days 15-21). Only the Pts-/- mice with ‘low’ treatment seemed to be
slightly different from their normal littermates, as they had reduced growth rate almost
from birth (see ‘low’ at day 3 in Fig. 3). This developmental difference in the ‘low’ 
treatment group was even more pronounced later, as illustrated also in Figure 2D, which
shows a 7-day-old Pts-/- animal in comparison with an age-matched heterozygous
littermate. After the period of growth stagnation, the Pts-/- animals stopped gaining
weight independently of the treatment level, whereas all wild-type and heterozygous
mice grew normally. The diminutive body size of Pts-/- mice was best visible for those
that survived due to ‘high’ treatment, where the body weight was 34% of control at the
age of 7 weeks (7.8+1.5 grams for Pts-/- mice compared to 23.1+2.4 grams for
combined controls; Fig. 3 ‘medium’ and ‘high’ at day 23, 31, and 44). Further
qualitative characteristics of these otherwise healthy dwarf mice included reduced
activity, hypersalivation, difficulty to swallow, dystonia, tremor, and no signs of sexual
maturation. Additional but less pronounced or steady characteristics were fair hair due
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to light pigmentation, hair loss, and hypothermia. In summary, treatment of Pts-/- mice
with BH4 and neurotransmitter precursors resulted in rescue from lethality but severe
dwarfism. 
Biochemical analysis of sacrificed mice following different treatment protocols
For enzymatic and metabolite analyses in liver, blood, and brain, all groups of treated
mice were sacrificed at day 23 for ‘low’, day 31 for ‘medium’, and day 44 for ‘high’ 
treatment. Liver analysis was also carried out with untreated mice at day 1 after birth
(see above), whereas the limited brain material from newborns allowed us to measure
only nitrite+nitrate (compare to Tables 2 and 3). 
As expected, PTPS activity in liver and brain was completely abolished in the Pts-
knockout mice, and reduced to roughly 45% in heterozygous animals compared to
wild-type. Furthermore, in liver and brain of phenotypically normal mice, i.e. wild-
type and heterozygotes, PTPS activity increased with age. Independent of the treatment
level, blood phenylalanine, and liver BH4 and GTPCH activity decreased in 23, 31, and
44-day-old knockout mice compared to controls. Low GTPCH activity in Pts-/- mice
was surprising since it was expected that hyperphenylalaninemia and low BH4-levels,
as observed in these mice, results in an increase of GTPCH activity via the stimulatory
action of GFRP (6) (see also Discussion). 
Brain serotonin was severely lowered only in 23-day-old knockout mice with the ‘low’ 
treatment, but approximately 50% of normal in knockouts with ‘medium’ or ‘high’ 
treatment. Instead, brain dopamine was not detectable in knockouts with the ‘low’ 
treatment and also very low, between 3-11% of control, in the ‘medium’ and ‘high’ 
treatment. The brain metabolites for dopamine and serotonin, HVA and 5-HIAA, were
only slightly reduced in Pts-/- mice even under the ‘high’ treatment conditions, with
52% of normal for HVA and 60% of normal for 5-HIAA (day 44 of treatment). Brain
dihydroxyphenlyacetic acid (DOPAC), which is the first degradation product of
dopamine following the action of dopamine hydroxylase (or MAO), was
indistinguishable among knockout and wild-type or heterozygous animals from the
‘medium’ and ‘high’ treatment groups (between 30.2-67.9 pmol/mg; not shown). 
The NOS activity in brain, as determined by measuring the sum of nitrate+nitrite,
revealed no difference among knockout and control animals, and was also independent
of treatment levels. NOS activity in the brain of untreated Pts-/- or normal mice at day
1 was several-fold higher compared to older animals, but also indistinguishable
between the phenotypes (100.0-117.3 nmol/g tissue at day 1). 
The Pts-/- knockout animals, independent of ‘medium’ or ‘high’ treatment conditions,
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exhibited extremely low dopamine and sub-optimal levels of BH4 and serotonin.
Furthermore, the only metabolic difference we observed among these two treatment
conditions, which eventually lead to death of animals with only the ‘medium’ treatment,
was the intermediate HPA.  
IGF-1 is severely lowered in rescued Pts-/- mice with dwarfism
As the phenotypic characteristics of the dwarf mice might be a consequence of
abnormal feeding behavior due to low dopamine and/or of hormonal deregulation, we
wondered whether the pituitary growth hormone (GH), the thyroid hormone thyroxin
(T4), and the insulin-like growth factor-1 (IGF-1) in serum of knockout animals were
reduced. As shown in Fig. 4, the serum IGF-1 levels in the knockout mice were reduced
by a factor of 7 in comparison with age-matched controls (knockouts 79+36 ng/ml;
controls 541+155 ng/ml). The expected sexual dimorphism between females (482+170
ng/ml) and males (613+113 ng/ml) is also clearly visible as published before (31).
Furthermore, we also tested whether the pituitary-derived growth hormone (GH) and
the thyroxin-stimulating hormone (TSH)-dependent thyroxin (T4) were also reduced in
these animals. However, we found no change in GH and T4 (not shown), indicating that
the pituitary gland is normally developed, and thus not the primary reason for dwarfism
in these treated Pts-/- mice. Low IGF-1 might thus be the biochemical reason for the
dwarfism, probably caused by the limiting brain dopamine, as abnormal feeding
behavior was reported in dopamine-deficient mice (see Discussion) (32).
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DISCUSSION
Here we report on treatment studies with a BH4-deficient mouse that was generated by
targeted disruption of the Pts locus that encodes the second enzyme in the BH4-
biosynthetic pathway. This model was sought to study the role of the cofactor in
metabolism and treatment. The importance of BH4 for dopamine and serotonin
production has been well established in patient studies, where treatment of cofactor
deficiency by replacement with the precursors L-Dopa and 5-hydroxytryptophan is
required for neurotransmitter homeostasis and essential for survival (1). The observation
that a complete knockout of BH4 biosynthesis in the mouse leads to a phenotype with
perinatal death fits the expectations regarding the absolute requirement of a cofactor
with central metabolic importance. The lack of biosynthetic activity for catecholamines,
which includes dopamine and norepinephrine, and for serotonin must be one of the
primary reasons for the perinatal death, as these neurotransmitters are essential for
postnatal survival (33). However, in contrast to humans patients, we were surprised to
find that the mice died almost immediately after birth with no visible abnormalities, an
observation that was also made by Sumi-Ichinose and co-workers, and published
during the course of our study (34). 
We found only a few knockout mice surviving for up to seven days after birth, probably
due to the BH4 present in mother’s milk (35), while the amount of milk available is in
turn dependent on the litter size and/or the mother’s behavior. Data from approximately
250 PTPS patients, as compiled in the database www.bh4.org, does not reveal perinatal
lethality, and although symptoms may be noted during the neonatal period,
abnormalities develop typically during the first weeks of life (1). Furthermore, low birth
weight and microcephaly, which is typical for PTPS deficiency in human newborns
(36), was not observed in our mice. On the other hand, symptoms like hypersalivation
and temperature instability are found in PTPS mice and human patients. Analysis of
metabolites showed HPA and neopterin accumulation due to complete absence of PTPS
activity, as expected (day 1 Table 2). Brain metabolites at this age were only determined
for NOS due to the limited material. However, monoamine neurotransmitters must be
low as inferred from measurements of 23-day-old knockouts under ‘low’ treatment that
died despite initial treatment, and had very low or not detectable brain serotonin and
dopamine levels. Although BH4 has a central role for the function of the three NOS
isoenzymes, i.e. vasorelaxation, immune response, and neurotransmission, no direct
association with such pathologies in BH4-deficient patients has been made. Only
recently, however, we found that patients revealed reduced NO metabolites in
cerebrospinal fluids independent of treatment. Implications from this study are that
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under BH4-deficient conditions NOS is uncoupled and produces by-products that are
neurotoxic and thus responsible for neuronal cell pathology through peroxynitrite
generation  (2) (37)(38). Regarding the NOS activity in our mutant mouse presented
here, we found no alterations in brain nitrate and nitrite levels, independently of
treatment level or age (Table 3). Furthermore, neither was the mouse brain NOS activity
reduced in untreated newborn knockouts, a phenomenon that may be explained by the
fact that mother milk contains high concentrations of BH4 and that all NOS have a low
 KD for BH4 binding compared to the aromatic amino acid hydroxylases (KD of 100-600
 µM compared to KD of 0.2 µM for nNOS) (39). Despite lethality during the first days of
life, which is not typical for BH4 deficiency in humans, we think that this Pts knockout
is a suitable animal model for studying the pathophysiology and treatment of BH4 
deficiency. 
During the initial treatment study where the recommended concentration of compounds
and precursors for the treatment of human patients was  administered orally (‘low’ 
treatment), we learned that this therapy did not rescue the mice. Accordingly, we found
no normalization of the metabolites that are followed today to control treatment in
human patients, i.e. plasma phe brain biopterin, HVA, and 5-HIAA  (Tables 2 and 3).
Furthermore, brain dopamine and serotonin were extremely low in the knockout mice
with ‘low treatment’. These neurotransmitters are below detection levels in human CSF
and can thus not be determined in patients. A simple explanation for the requirement of
higher doses of precursors and compounds for treatment may be the fact that mice have
a much higher metabolic rate than humans. For instance, the enzymatic efficiency of
PTPS is roughly ten times higher for the mouse compared to the human enzyme
(kcat/Km of recombinant PTPS from mouse is 2.5 x 104, and from human 2.8 x 103) (25). This
hypothesis was corroborated by the fact that we could eventually rescue the animals by
increasing the treatment doses . 
The biochemical parameters under ‘high’ treatment conditions revealed that plasma
phenylalanine was normalized, and biopterin was in the same range as in controls
(Tables 2 and 3). Serotonin and the neurotransmitter metabolites HVA and 5-HIAA
were in the subnormal range (approximately 50% of normal), whereas brain dopamine
was unexpectedly low at 3% of normal (see below). Furthermore, plasma and brain
neopterin remained elevated, and GTPCH was below normal activity, although
hyperphenylalaninemia is expected to result in an increase of GTPCH activity.
Moreover, under conditions of low BH4-levels, as in Pts-/- mice with ‘low’ treatment,
stimulation of GTPCH by the GTPCH-GFRP complex was expected to be even more
pronounced, as the inhibitory action of BH4 should also be diminished (4,6). Form the
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data presented here, we conclude that PTPS may have a direct or indirect effect on
GTPCH expression or GTPCH-GFRP activity. Regarding hyperphenylalaninemia,
increasing levels of oral BH4 lead to a gradually decrease of blood phenylalanine.
Whereas the ‘medium’ treatment exhibited an intermediate phenylalanine level, the
‘high’ treatment conditions were required to completely normalize blood phenylalanine
levels. A further observation that cannot be explained sufficiently at this point is that
knock-out animals under ‘medium’ treatment consistently did not survive for more than
4 weeks, whereas under ‘high’ treatment none of the mutants died. The only metabolic
difference we observed between these two treatment procedures was the slightly
elevated plasma phenylalanine levels in the animals treated with the ‘medium’ dose (see
Tables 2 and 3). It is unlikely that a mild HPA has such a dramatic effect on growth and
development, and additional treatment studies have to be conducted to learn more about
these differences. 
The most remarkable observation made while treating the Pts-/- mice was the
consistently reduced growth starting almost from the first days of life, leading to
dwarfism. Normal growth and development are largely programmed during the first
weeks of postnatal life by the pituitary growth hormone (GH) and thyroxin-stimulating
hormone (TSH)(40). Furthermore, somatic growth is mediated mainly by circulating
IGF-I, an insulin-like hormone produced mainly in the liver but also in many other
tissues. At least two examples of dwarf mice are well described: the so-called Ames
and Snell dwarf mice with recessive mutations in the homeotic genes Pit-1 or Prop-1, 
respectively, with developmental arrest in pituitary ontogeny (40). Phenotypic
characteristics are decreased growth rate post-weaning, and reduced body size of
adults, having approximately one third of the weight of their normal siblings, similar to
what we found in our Pts knockout mice. Further characteristics reminiscent of our
dwarf mice include delayed puberty, reduction of body temperature, tendency to
experience hair loss, and reduction in plasma IGF-1. This prompted us to determine
these hormones in our treated mice. In contrast to the Ames and Snell dwarf mice, we
found normal levels for the pituitary GH and TSH-dependent T4, indicating that the
pituitary gland developed normally and can thus be excluded as the primary reason for
dwarfism of treated Pts-/- mice. The IGF-1 level is influenced by GH but also by the
nutritional status and food intake, which in turn is regulated by the dopamine and
norepinephrine levels (41,42)(43). For instance, it was reported that a knockout mouse
that does not express tyrosine hydroxylase was unable to initiate feeding, an ability that
can be restored by gene delivery of tyrosine hydroxylase into the striatum (32,33,44,45).
As also mentioned before, we found that the brain serotonin, and the neurotransmitter
metabolites HVA, DOPAC and 5-HIAA, although slightly below normal, were not
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much different from control levels. This is in sharp contrast with the actual dopamine
levels of 3% of normal in the brain of mice under ‘high’ treatment. Furthermore, the
DOPAC/dopamine ratio (and the HVA/dopamine ratio), which is an index of dopamine
turnover rate, was 1.8 in the wild-type and heterozygous mice group under ‘medium’ 
and ‘high’ treatment, but was 48 in both knockout mice groups, presumably reflecting
the high turnover of the small dopamine pool (not shown). The extremely low brain
dopamine together with the wealth of literature on the feeding behavior in dopamine-
deficient mice mentioned above supports the assumption that abnormal (hypothalamic)
neurotransmission is associated in our mice with disturbance of eating behavior.
Although we did not measure daily food or water intake, we consistently observed
difficulties to swallow in our knockout mice groups and conclude that control of
appetite is compromised in the treated Pts-/- mice and thus chronic undernutrition is
responsible for low IGF-1 and dwarfism. Such feeding difficulties have been described
for BH4-deficient patients, but so far there was no indication of growth retardation or
dwarfism. Nevertheless, we tested for IGF-1 in a first study with a very small group of
BH4-deficient patients and found specifically reduced plasma IGF-1 levels in
newborns with PTPS deficiency. Although these results are only preliminary, we
believe it will be important to collect more data on IGF-1 levels and to follow growth
and development in human patients with BH4-deficiency. 
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LEGENDS TO FIGURES
Figure 1. Targeted disruption of the murine Pts gene. (A) Genomic structure of the Pts 
wild-type allele containing the 6 exons, the targeting vector (pMSY23), and the
expected targeted allele with the in-frame lacZ and the Pgk-neo insertion, replacing
exons 3 and 4 plus most of exon 2. Position of the primers a-c for PCR analysis, and
probes for Southern analysis are indicated. E, EcoRI; H, HindIII (B) Genetic analysis of
F1-hybrid mice by multiplex PCR with genomic DNA as template and the 3 primers
a,b, and c: while primer a is upstream of exon 2 and thus present in wild-type and
mutant alleles, primer b is specific for exon 2, and primer c is specific for lacZ. The
multiplex PCR with primer pair a/b results in a DNA fragment of 315 bp, and with
primers a/c in 354 bp. (C) Southern blot analyses of genomic DNA with either wild-
type ES cell clone 129/Sv (‘wt’) and the targeted ES cell clone (7-E3; ‘hetero’), or
mouse tail DNA from wild-type, heterozygous or Pts-knockout mice. Genomic DNA
was digested with EcoRI and hybridized with the 5’-external probe A. The endogenous
wild-type fragment is 7.5 kb, whereas the targeted fragment is 6.4 kb in size. 
Figure 2. Growth behavior following BH4, L-Dopa, and 5-hydroxytryptophan
treatment of Pts-/- and control mice. Growth curves of colonies with ‘low’ (A),
‘medium’ (B), and ‘high’ (C) treatment are shown. Full lines are for Pts-/- animals (3
in A, 5 in B, and 6 in C), whereas the dashed lines are for the wild-type or heterozygous
animals (14 in A, 13 in B, and 7 in C). (D) Comparison of a 7-day-old Pts-/- mouse
with a heterozygous healthy littermate. Both animals were treated with the ‘low’ dose.
Details are described in the text.  
Figure 3. Statistical analysis of data points from growth curves with ‘low’, ‘medium’, 
and ‘high’ treatment. Shown are mean value and standard deviations for animals with
‘low’ treatment at days 3 and 23, ‘medium’ treatment at days 3, 23, and 31, and ‘high’ 
treatment at days 3, 23, 31, and 44 (ko, knockout; h, heterozygous; wt, wild-type).
Significant difference is indicated by asterisks: *, p<0.05; **, p<0.01; ***, p<0.005
(Student’s t test).
Figure 4. Serum IGF-1 levels for 44-day-old mice under ‘high’ treatment. Mean
values and standard deviations in ng/ml are shown for normal animals (wild-type and
heterozygote; n = 9) and knockouts (n = 6). The first bar is IGF-1 for both sex (f + m),
whereas f is for females and m for males only.
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Table 1: Treatment protocol for oral application of BH4 and neurotransmitter precursors 
Compound 1 low 2 medium high
(µg/g body weight/day)
___________________________________________________
BH4 10 60 122
L-Dopa 5 10.6 13.5
5-Hydroxytryptophan 3 7.4 9.5
Carbidopa 3 2.5 2.5 2.5
Ascorbic acid 4 10 50 100
N-Acetyl-L-cysteine 4 5 25 50
___________________________________________________
1
 The daily doses for the ‘medium’ and ‘high’ treatments were given in 2 applications, one in the morning, and one in the late 
afternoon.
2
 The ‘low’ treatment corresponds to the recommended standard concentrations for treatment of human patients (Blau et al., 2002).
3
 Decarboxylase inhibitor.
4
 Antioxydant.
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Table 2: Mouse liver values for GTPCH and PTPS enzymes and their metabolites neopterin and biopterin
Age (days Genotype Treatment 1 GTPCH 2 PTPS 2 Neopterin 2 Biopterin 2 Phenylalanine 3
after birth) (µU/mg) (µU/mg) (pmol/mg) (pmol/mg) (µmol/l)
_________________________________________________________________________________________________________________________________
1 k.o. none 0.21 (0.1-0.3) < 0.05 59.0 (37.1-77.7) 0.9 (0.7-1.1) 1352 (1290-1415)
heterozygote 0.21 (0.1-0.3) 1.5 (0.9-4.3) 1.2 (0.9-1.6) 12.5 (12.1-13.2) n.m.
wild-type 0.27 (0.2-0.3) 8.0 (3.6-14.8) 0.3 (0.3-0.3) 21.0 (20.6-21.6) n.m.
23 k.o. low 1.3 (0.9-1.7) < 0.05 144 (73.8-213.3) 0.6 (0.6-0.6) 993 (02-1060)
heterozygote 2.2 (1.3-3.2) 8.7 (4.5-12.0) 0.1 (0.1-0.3) 26.1 (12.3-35.9) 92 (52-140)
wild-type 2.3 (1.4-4.9) 18.4 (15.3-23.3) n.d. 22.9 (9.3-28.9) 94 (58-112)
31 k.o. medium 0.8 (0.7-0.8) < 0.1 75.6 (39.8-140.8) 64.3 (10.2-152.5) 437 (152-717)
heterozygote 1.6 (1.5-1.6) 8.6 (7.7-9.6) 0.5 (0.1-1.0) 20.0 (17.1-22.3) 47 (39-57)
wild-type 1.2 (1.1-1.6) 21.4 (18.2-24.8) 0.5 (0.2-0.9) 18.6 (14.7-20.8) 43 (34-56)
44 k.o. high 0.6 (0.5-0.9) < 0.1 19.8 (16.4-26.7) 24.5 (0.9-54.3) 56 (42-85)
heterozygote 1.8 (1.6-1.9) 6.5 (5.9-7.0) 1.4 (1.3-1.5) 23.5 (22.1-24.2) 50 (37-73)
wild-type 1.5 (0.8-1.9) 17.5 (13.0-20.3) 0.7 (0.1-1.4) 23.3 (17.6-29.7) 55 (40-73)
_________________________________________________________________________________________________________________________________
n.m., not measured.
1
 See Table 1 and Materials and Methods for treatment conditions.
2
 Indicated are mean values and ranges (in parenthesis); for each age group 3-7 animals were tested, except only 2 k.o.-animals for ‘none’ and ‘low’ treatment.
3
 Phenylalanine was measured by Tandem-MS in blood spots (Guthrie cards). For the non-treated mice, blood phenylalanine was determined at day 7. 
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Table 3: Mouse brain values for GTPCH and PTPS enzymes and their metabolites, plus neurotransmitter and nitrite+nitrate values
Age 1 Genotype Treatment 2 GTPCH 3 PTPS 3 Neopterin 3 Biopterin 3 Dopamine 3 HVA 3,4 Serotonin 3 5-HIAA 3,5 NO 3,6
(µU/mg) (µU/mg) (pmol/mg) (pmol/mg) (pmol/mg) (pmol/mg) (pmol/mg) (pmol/mg) (nmol/g tissue)
______________________________________________________________________________________________________________________________________________________________
23 k.o. low 0.07 (0.06-0.08) n.m. 7.0 (6.1-7.9) 0.9 (0.8-1.0) n.d. 0.5 (n.d.-1.0) 0.3 7.5 (4.9-10.1) 21.0 (20.5-21.5)
heterozygote 0.1 (0.06-0.14) 16.3 (2.4-24.3) < 0.01 6.4 (3.3-10.1) 16.8 (14.5-21.1) 22.6 (19.9-26.9) 4.8 (3.3-6.4) 63.3 (56.2-75.1) 30.9 (27.1-36.8)
wild-type 0.09 (0.06-0.14) 26.0 (1.9-46.8) < 0.05 4.6 (2.3-6.2) n.m. 15.4 n.m. 57.2 29.7 (29.4-30.0)
31 k.o. medium 0.09 (0.09-0.10) < 0.05 5.3 (4.6-6.9) 4.8 (2.2-7.9) 3.5 (0.9-5.1) 18.4 (2.3-28.7) 6.0 (1.8-8.8) 44.9 (19.7-66.5) 22.0 (20.0-24.8)
heterozygote 0.10 (0.08-0.12) 31.9 (25.7-42.0) < 0.01 6.9 (6.6-7.0) 34.1 (28.9-41.9) 22.1 (17.9-28.2) 9.7 (8.9-10.1) 58.2 (52.9-62.6) 37.9 (19.7-69.1)
wild-type 0.12 (0.09-0.14) 72.5 (69.7-75.5) 0.13 (0-0.4) 6.9 (6.4-7.3) 28.2 (26.6-29.0) 23.2 (18.8-26.8) 9.4 (9.1-9.5) 63.6 (55.2-71.2) 21.3 (14.9-30.9)
44 k.o. high 0.08 (0.07-0.09) < 0.05 4.5 (4.0-5.5) 5.5 (2.1-11.4) 1.2 (0.4-2.1) 12.0 (0.7-22.8) 4.8 (1.0-7.0) 36.8 (9.9-50.5) 20.7 (17.4-28.0)
heterozygote 0.12 (0.09-0.13) 29.7 (26.9-33) < 0.05 12.8 (6.6-24.8) 37.2 (30.7-44.9) 23.8 (20.7-25.9) 12.0 (10.6-13.3) 60.0 (58.7-62.5) 21.2 (20.5-22.8)
wild-type 0.12 (0.11-0.15) 72.0 (67-74.8) < 0.01 7.0 (6.6-7.8) 38.1 (32.1-43.7) 22.1 (20.1-24.8) 9.2 (7.5-11.8) 63.3 (55.5-74.5) 29.6 (26.1-34.2)
_________________________________________________________________________________________________________________________________
n.d., not detectable; n.m., not measured.
1
 Days after birth. Note that from the brain of 1-day old mice not enough material could be prepared for these analyses. 
2
 See Table 1 and Materials and Methods for treatment conditions.
3
 Indicated are mean values and ranges (in parenthesis); for each age group 3-4 animals were tested, except for ‘low’ treatment, where in some instances only 
two or one animal(s) were available for analysis. 
4
 HVA, homovanillic acid.
5
 5-HIAA, 5-hydroxyindoleacetic acid.
6
 NO, nitric oxide; sum of nitrite (NO2-) and nitrate (NO3-). 
 at Hauptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on February 9, 2010www.jbc.orgDownloaded from 
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on February 9, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on February 9, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on February 9, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on February 9, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on February 9, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on February 9, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on February 9, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on February 9, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on February 9, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
